VEGFR-3 expression profiling by histology and biomarkers strategy to classify patient population for the selective VEGFR-3 inhibitor EVT801
Recently presented by Evotec colleagues in collaboration with Kazia Therapeutics at the ESMO 2023 conference. View the scientific poster below.